NRX Pharmaceuticals Inc (NASDAQ:NRXP) — Market Cap & Net Worth
Market Cap & Net Worth: NRX Pharmaceuticals Inc (NRXP)
NRX Pharmaceuticals Inc (NASDAQ:NRXP) has a market capitalization of $58.91 Million ($58.91 Million) as of June 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21345 globally and #4722 in its home market, demonstrating a 2.84% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NRX Pharmaceuticals Inc's stock price $3.98 by its total outstanding shares 29605150 (29.61 Million). Review NRX Pharmaceuticals Inc (NRXP) financial obligations to assess the company's total debt and financial obligations.
NRX Pharmaceuticals Inc Market Cap History: 2017 to 2026
NRX Pharmaceuticals Inc's market capitalization history from 2017 to 2026. Data shows change from $2.87 Billion to $117.83 Million (-31.12% CAGR).
Index Memberships
NRX Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #614 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2054 of 3165 |
Weight: NRX Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
NRX Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NRX Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NRXP by Market Capitalization
Companies near NRX Pharmaceuticals Inc in the global market cap rankings as of June 19, 2026.
Key companies related to NRX Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
NRX Pharmaceuticals Inc Historical Marketcap From 2017 to 2026
Between 2017 and today, NRX Pharmaceuticals Inc's market cap moved from $2.87 Billion to $ 117.83 Million, with a yearly change of -31.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $117.83 Million | +46.86% |
| 2025 | $80.23 Million | +23.18% |
| 2024 | $65.13 Million | -52.17% |
| 2023 | $136.18 Million | -58.56% |
| 2022 | $328.62 Million | -76.78% |
| 2021 | $1.42 Billion | -80.41% |
| 2020 | $7.22 Billion | +130.19% |
| 2019 | $3.14 Billion | +3.92% |
| 2018 | $3.02 Billion | +5.37% |
| 2017 | $2.87 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of NRX Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $58.91 Million USD |
| MoneyControl | $58.91 Million USD |
| MarketWatch | $58.91 Million USD |
| marketcap.company | $58.91 Million USD |
| Reuters | $58.91 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About NRX Pharmaceuticals Inc
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in p… Read more